Saturday, November 21, 2026The 2020–2026 archive is restored at its original addresses · RSS
I Health TodayIndigenous health, employment and community news in Canada
⌛Historical document. This page is restored from the original Indigenous Health Today (2020–2026, operated by NationTalk) exactly as published, at its original address. Details may be out of date. Source snapshot: Wayback Machine, Dec 2, 2020. Not affiliated with or endorsed by NationTalk or any organization referenced.

Expensive gene therapies raise challenges and opportunities: Expert panel report

Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country. However, there are opportunities to control spending, streamline approvals and support fair access through innovation, coordination and collaborat

· archived

Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country. However, there are opportunities to control spending, streamline approvals and support fair access through innovation, coordination and collaboration, according to a new expert panel report from the Council of Canadian Academies (CCA).

“Rapid scientific advances mean potentially life-changing treatments are approaching the clinic at an accelerated pace,” said Janet Rossant, PhD, C.C., FRSC, and Chair of the Expert Panel. “These new therapies, however, pose a number of challenges in terms of their introduction into the Canadian healthcare system and ensuring access to those who would most benefit.”

The National Research Council of Canada asked the CCA to examine the key legal, regulatory, ethical, social and policy challenges specific to the approval and use of somatic gene and engineered cell therapies in Canada.

Somatic gene and engineered cell therapies treat disease by removing or modifying existing genetic material in a patient, or introducing new genetic material, without passing these changes to future generations. Most treat rare genetic disorders and cancers, however they can cost more than $1 million and have limited evidence of long-term safety and durability.

From Research to Reality describes the stages involved in the approval and use of gene therapies in Canada, and examines the challenges associated with regulatory oversight, manufacturing, access, and affordability. It also identifies emerging solutions that can capitalize on Canadian strengths in research, manufacturing and health-care accessibility.

“The approval and use of gene therapies challenges payers, regulators, industry, patients and families,” said Eric M. Meslin, PhD, FCAHS, President and CEO of the CCA. “This report covers many of these challenges as well as possible paths forward, and will help to support evidence-informed decision making in Canada.”

Visit www.cca-reports.ca to download the report.

From Research to Reality will be featured at Breaking Through, the 2020 Gairdner International Ontario Symposium on Thursday, December 3, 2020. Information and registration is available at www.breaking-through.ca.

-30-

Contact:

Heather Ennis
Director of Communications, Council of Canadian Academies 613-851-7723
[email protected]

IHT5

Education

UCalgary: Modern medicine integrates Indigenous ways of healing

· archived

Press Release

Education

RRU: Combat experience, cultural skills and COVID-19

· archived

Press Release

Education

USask awarded $650K to work with First Nations and Métis communities to address the impacts of COVID-19

· archived

Press Release

Education

NVIT to train more community mental health workers

· archived

BURNABY – A new education and training program at Nicola Valley Institute of Technology (NVIT) will enable people to train for high-demand jobs as community mental health workers.